文献速递妇科肿瘤

TP53测序与p53免疫组化预测贝伐珠单抗加入子宫内膜癌一线化疗后的结局:NRG肿瘤学/妇科肿瘤组研究

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
PubMed 文献 · J Clin Oncol · 2022-06-03

本研究基于GOG-86P随机II期试验,分析213例晚期子宫内膜癌患者的p53免疫组化(IHC)与TP53二代测序(NGS)数据。p53过表达者中,化疗联合贝伐珠单抗较联合替西罗莫司显著改善无进展生存(PFS HR 0.46)和总生存(OS HR 0.31)。TP53错义突变伴p53蛋白过表达者同样显示贝伐珠单抗获益。

要点

  • p53 IHC过表达患者中,贝伐珠单抗联合化疗较替西罗莫司联合化疗显著改善PFS(HR 0.46)和OS(HR 0.31)。
  • TP53错义突变且p53蛋白过表达者,贝伐珠单抗联合化疗的PFS HR 0.41、OS HR 0.28。
  • TP53 NGS与p53 IHC总体一致率为88%,排除TP53突变合并POLE突变或错配修复缺陷病例后为92%。

核心结论

  • p53 IHC单独或与TP53测序整合可识别高危肿瘤基因型/表型,此类患者化疗联合贝伐珠单抗可改善结局。

研究设计与样本

  • GOG-86P随机II期研究,比较化疗联合贝伐珠单抗或替西罗莫司在晚期子宫内膜癌中的疗效,213例有p53 IHC和TP53 NGS数据。

主要发现

  • p53过表达者中,贝伐珠单抗联合化疗较替西罗莫司联合化疗的PFS HR为0.46(95%CI 0.26-0.88),OS HR为0.31(95%CI 0.16-0.62)。
  • TP53错义突变且p53蛋白过表达者中,贝伐珠单抗联合化疗较替西罗莫司联合化疗的PFS HR为0.41(95%CI 0.22-0.83),OS HR为0.28(95%CI 0.14-0.59)。
  • TP53 NGS与p53 IHC一致率为88%;排除TP53突变合并POLE突变或错配修复缺陷病例后一致率为92%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The status of p53 in a tumor can be inferred by next-generation sequencing (NGS) or by immunohistochemistry (IHC). We examined the association between p53 IHC and sequence and whether p53 IHC alone, or integrated with TP53 NGS, predicts the outcome. METHODS: From GOG-86P, a randomized phase II study of chemotherapy combined with either bevacizumab or temsirolimus in advanced endometrial cancer, 213 cases had p53 protein expression data measured by IHC and TP53 NGS data. An analysis was designed to integrate p53 expression by IHC with the presence or absence of a TP53 mutation. These variables were further correlated with progression-free survival (PFS) and overall survival (OS) in the chemotherapy plus bevacizumab arms versus the chemotherapy plus temsirolimus arm. RESULTS: In the analysis of p53 IHC, the most striking treatment effect favoring bevacizumab was in cases where p53 was overexpressed (PFS hazard ratio [HR]: 0.46, 95% CI, 0.26 to 0.88; OS HR: 0.31, 95% CI, 0.16 to 0.62). On integrated analysis, patients with TP53 missense mutations and p53 protein overexpression had a similar treatment effect on PFS (HR: 0.41, 95% CI, 0.22 to 0.83) and OS (HR: 0.28, 95% CI, 0.14 to 0.59) favoring bevacizumab plus chemotherapy relative to temsirolimus plus chemotherapy. Concordance between TP53 NGS and p53 IHC was 88%. Concordance was 92% when cases with TP53 mutations and POLE mutations or mismatch repair deficiency were removed. CONCLUSION: IHC for p53 alone or when integrated with sequencing for TP53 identifies a specific, high-risk tumor genotype/phenotype for which bevacizumab is particularly beneficial in improving outcomes when combined with chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Thiel KW, Devor EJ, Filiaci VL, et al. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022. PMID: 35658479. doi:10.1200/JCO.21.02506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。